These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27211699)

  • 1. Serum metabonomics of NAFLD plus T2DM based on liquid chromatography-mass spectrometry.
    Chen Y; Li C; Liu L; Guo F; Li S; Huang L; Sun C; Feng R
    Clin Biochem; 2016 Sep; 49(13-14):962-6. PubMed ID: 27211699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum metabolite signatures of type 2 diabetes mellitus complications.
    Wu T; Xie G; Ni Y; Liu T; Yang M; Wei H; Jia W; Ji G
    J Proteome Res; 2015 Jan; 14(1):447-56. PubMed ID: 25245142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry.
    Tsutsui H; Maeda T; Min JZ; Inagaki S; Higashi T; Kagawa Y; Toyo'oka T
    Clin Chim Acta; 2011 May; 412(11-12):861-72. PubMed ID: 21185819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
    Li YL; Xie H; Musha H; Xing Y; Mei CX; Wang HJ; Wulasihan M
    Cell Biochem Biophys; 2015 Jul; 72(3):643-7. PubMed ID: 27352181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Miyasato M; Murase-Mishiba Y; Bessho M; Miyawaki M; Imbe H; Tsutsumi C; Tanimoto K; Imagawa A; Terasaki J; Hanafusa T
    Clin Chim Acta; 2014 Jun; 433():184-9. PubMed ID: 24667697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system.
    Zhang J; Yan L; Chen W; Lin L; Song X; Yan X; Hang W; Huang B
    Anal Chim Acta; 2009 Sep; 650(1):16-22. PubMed ID: 19720167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.
    Tiwari-Heckler S; Gan-Schreier H; Stremmel W; Chamulitrat W; Pathil A
    Nutrients; 2018 May; 10(5):. PubMed ID: 29883377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry.
    Tsutsui H; Maeda T; Toyo'oka T; Min JZ; Inagaki S; Higashi T; Kagawa Y
    J Proteome Res; 2010 Aug; 9(8):3912-22. PubMed ID: 20557141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of amino acids and acylcarnitines combined with untargeted metabolomics using ultra-high performance liquid chromatography and quadrupole time-of-flight mass spectrometry.
    Roy C; Tremblay PY; Bienvenu JF; Ayotte P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():40-9. PubMed ID: 27240302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry.
    Hu C; Zhuang X; Zhang J; Wang T; Du S; Wang J; Peng X; Cao Q; Zhang M; Jiang Y
    Lab Med; 2022 Jul; 53(4):360-368. PubMed ID: 35075477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UPLC-MS-based serum metabonomics for identifying acute liver injury biomarkers in Chinese miniature pigs.
    Ma J; Yu J; Su X; Zhu C; Yang X; Sun H; Chen D; Wang Y; Cao H; Lu J
    Toxicol Lett; 2014 Mar; 225(3):358-66. PubMed ID: 24451218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Circulating CTRP13 in Type 2 Diabetes and Non-Alcoholic Fatty Liver Patients.
    Shanaki M; Fadaei R; Moradi N; Emamgholipour S; Poustchi H
    PLoS One; 2016; 11(12):e0168082. PubMed ID: 27936230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry.
    Luo P; Yu H; Zhao X; Bao Y; Hong CS; Zhang P; Tu Y; Yin P; Gao P; Wei L; Zhuang Z; Jia W; Xu G
    J Proteome Res; 2016 Apr; 15(4):1288-99. PubMed ID: 26889720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Zhang J; Zhang B; Cheng Y; Xu J
    Cytokine; 2018 Jun; 106():131-135. PubMed ID: 29113741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated biomarker for type 2 diabetes mellitus and impaired fasting glucose based on metabolomics analysis using ultra-high performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry.
    Long J; Liu L; Jia Q; Yang Z; Sun Z; Yan C; Yan D
    Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8779. PubMed ID: 32159245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy.
    Zhu C; Liang QL; Hu P; Wang YM; Luo GA
    Talanta; 2011 Sep; 85(4):1711-20. PubMed ID: 21872008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.